SCHEMBL22952995

SCHEMBL22952995

COc1cc(C2Oc3c(ccc(O)c3O)C3CNCCC32)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.43
DRD5 P21918 2/20 0.43
ADRA2A P08913 1/20 0.43
DRD2 P14416 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
DRD3 P35462 1/20 0.43
PTGS1 P23219 1/20 0.35
ESR1 P03372 3/20 0.34
ESR2 Q92731 3/20 0.34
FYN P06241 1/20 0.32
TLR9 Q9NR96 2/20 0.31
TLR8 Q9NR97 2/20 0.31
TLR7 Q9NYK1 2/20 0.31
CYP3A4 P08684 1/20 0.31
ALOX5 P09917 1/20 0.31
PTPN1 P18031 1/20 0.31
PPARG P37231 1/20 0.31
PPARD Q03181 1/20 0.31
HTR6 P50406 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22953349 0.88 ADRA2A (0.44) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22953352 0.88 ADRA2A (0.44) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22952998 0.88 ADRA2A (0.46) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22953350 0.87 ESR1 (0.35) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22953348 0.86 ADRA2A (0.44) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22953347 0.86 ADRA2A (0.44) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22953351 0.83 ADRA2A (0.42) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22953000 0.83 ADRA2A (0.49) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL22952936 0.80 DRD1 (0.63) DRD1DRD5ADRA2ADRD2ADRA2B
SCHEMBL25308161 0.69 PDE4B (0.51) TLR9TLR8TLR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021021922-A1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-02-04 WO disclosed